tislelizumab + lenalidomide

tislelizumab + lenalidomide is a combination therapy being evaluated for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), particularly in elderly patients with the non-germinal center B-cell (non-GCB) subtype. Tislelizumab is a humanized IgG4 monoclonal antibody developed by BeiGene that functions as a checkpoint inhibitor by binding to the programmed cell death protein 1 (PD-1) receptor on T cells. This blockade prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2, thereby reversing immune suppression and enhancing the anti-tumor activity of T cells. Lenalidomide is an oral immunomodulatory drug (IMiD) that binds to cereblon, a component of the E3 ubiquitin ligase complex. This binding triggers the degradation of specific transcription factors, such as Ikaros and Aiolos, leading to direct anti-proliferative effects in B-cell malignancies and stimulation of T-cell and natural killer (NK) cell activity. The combination is currently being investigated in a Phase Ib/II clinical trial (NCT04404075) led by investigator Huiqiang Huang at Sun Yat-sen University Cancer Center.

Brand names

TevimbraRevlimid

Other names

PD-1 antibodyPD1 antibodyPD 1 antibodylenalidomide